Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Terns Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 45 | 65 | +20 |
| Shares | 30.3M | 49.7M | +19.4M (+64.2%) |
| Value | $178.1M | $506.2M | +$328.1M (+184.2%) |
New holders (25)
Institutions that held Terns Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (5)
Institutions that held Terns Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Commodore Capital LP | 205,870 | $1.21M |
| Raymond James Financial Services Advisors, Inc. | 20,830 | $123.0K |
| Charles Schwab Investment Management Inc | 12,408 | $74.0K |
| Prelude Capital Management, LLC | 10,945 | $64.0K |
| UBS Group AG | 3,667 | $22.0K |